DRTS vs. OBIO, QIPT, DCTH, CVRX, PROF, CLPT, ARAY, TELA, RCEL, and NPCE
Should you be buying Alpha Tau Medical stock or one of its competitors? The main competitors of Alpha Tau Medical include Orchestra BioMed (OBIO), Quipt Home Medical (QIPT), Delcath Systems (DCTH), CVRx (CVRX), Profound Medical (PROF), ClearPoint Neuro (CLPT), Accuray (ARAY), TELA Bio (TELA), AVITA Medical (RCEL), and NeuroPace (NPCE). These companies are all part of the "surgical & medical instruments" industry.
Alpha Tau Medical (NASDAQ:DRTS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.
In the previous week, Alpha Tau Medical and Alpha Tau Medical both had 8 articles in the media. Orchestra BioMed's average media sentiment score of 1.24 beat Alpha Tau Medical's score of 0.12 indicating that Orchestra BioMed is being referred to more favorably in the news media.
Alpha Tau Medical has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Alpha Tau Medical has higher earnings, but lower revenue than Orchestra BioMed. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 53.5% of Orchestra BioMed shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 6.7% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Alpha Tau Medical received 6 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 60.00% of users gave Alpha Tau Medical an outperform vote.
Alpha Tau Medical currently has a consensus target price of $12.00, suggesting a potential upside of 342.80%. Orchestra BioMed has a consensus target price of $17.00, suggesting a potential upside of 230.10%. Given Alpha Tau Medical's higher possible upside, equities research analysts clearly believe Alpha Tau Medical is more favorable than Orchestra BioMed.
Alpha Tau Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -2,330.46%. Alpha Tau Medical's return on equity of -31.86% beat Orchestra BioMed's return on equity.
Summary
Alpha Tau Medical beats Orchestra BioMed on 10 of the 15 factors compared between the two stocks.
Get Alpha Tau Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Tau Medical Competitors List
Related Companies and Tools
